Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …

Psychiatric patients have a greater risk of premature mortality, predominantly due to
cardiovascular diseases (CVDs). Convincing evidence shows that psychiatric conditions are …

Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive
allosteric modulator in development for the treatment of schizophrenia. We aimed to …

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

Rosmarinus officinalis L.(rosemary) is a medicinal plant native to the Mediterranean region
and cultivated around the world. Besides the therapeutic purpose, it is commonly used as a …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports on the most up-to-date statistics related to heart disease, stroke …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical
antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it …

Drug‐induced toxicity is a key issue for public health because some side effects can be
severe and life‐threatening. These adverse effects can also be a major concern for the …

A retrospective data analysis using 2000–2008 three state Medicaid Analytic eXtract was
conducted to examine the prevalence and association of comorbidities (psychiatric and non …